Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.10 (-0.38%)
Bid:
26.50
Ask:
26.90
Spread: 0.40 (1.509%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Senior Executive Incentive Package

24 Sep 2010 12:00

RNS Number : 2654T
EKF Diagnostics Holdings PLC
24 September 2010
 



EKF Diagnostics Holdings plc

("EKF" or "the Company")

 

Senior Executive Incentive Package

 

The Board recognises the importance of incentivising and rewarding the performance of its key executives and recently tasked the remuneration committee to recommend to the Board an appropriate long term incentive plan for its senior executives.

 

The Board, following the recommendation of the remuneration committee and after consulting its advisers, has today made the following awards to each of David Evans (Executive Chairman) and Julian Baines (Chief Executive Officer) under the Company's existing incentive plan which was adopted on 25 November 2009:

 

• options over 8,545,638 ordinary shares, representing 6 per cent. of the current issued share capital, divided equally between Mr Evans and Mr Baines. These options are exercisable at 15p per share, the price at which the placing to raise £15.06m took place in July 2010. These options are subject to the achievement of 15 per cent. compound annual EBITDA growth for the three years commencing on 1 January 2011. The base EBITDA will be equal to twice the audited EBITDA achieved by EKF Holdings plc for the 6 months ending 31 December 2010; and

 

• options over a further 8,545,638 ordinary shares, representing 6 per cent. of the current issued share capital, again divided equally between Mr Evans and Mr Baines. These options are exercisable at 15p per share, conditional upon the share price reaching 45p per share, a trebling of the 15p per share price at which the recent placing was undertaken, within the three years commencing 1 January 2011.

 

All other terms and conditions of these incentivisation arrangements are in conformity with the Company's existing incentive plan.

 

Related Party Transaction

The issue of options is a related party transaction. Under the AIM Rules, when a company enters into a related party transaction the independent directors to the transaction, after consultation with the Company's NOMAD, must consider whether the transaction is fair and reasonable insofar as the shareholders are concerned. The Directors, other than David Evans and Julian Baines, consider (after consultation with Zeus Capital, the Company's NOMAD, who have taken into account the commercial assessment of the independent directors) that the transaction is fair and reasonable insofar as the shareholders are concerned.

 

Comment from the Chairman of the Remuneration committee, Gordon Hall:

"It is important that David and Julian are rewarded in a way which links their performance with shareholder value creation. I am satisfied that these incentivisation arrangements achieve that objective".

 

Enquiries:

 

EKF Diagnostics Holdings plc

Julian Baines, CEO

Paul Foulger, FD

 

Tel: 020 7823 1733

Mob: 07788 420 859

Zeus Capital - Nominated Adviser and Joint Broker

Ross Andrews

Tom Rowley

 

Tel: 0161 831 1512

Matrix Corporate Capital LLP - Joint Broker

Tel: 020 3206 7000

Robert Naylor

 

 

Walbrook PR

Paul McManus

 

Tel: 020 7933 8780

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFFIARISFII
Date   Source Headline
20th May 20265:41 pmRNSLong Term Incentive Plan Award
19th May 202612:24 pmRNSResult of AGM
19th May 20267:00 amRNSAGM statement & positive Q1 trading update
27th Apr 20267:00 amRNSBoard Changes
24th Apr 20264:43 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSAcquisition of assets from Beep Insights
10th Apr 20269:12 amRNSShare Buyback
8th Apr 20262:33 pmRNSShare Buyback
7th Apr 20261:09 pmRNSShare Buyback
2nd Apr 20267:00 amRNSShare Buyback
31st Mar 20265:59 pmRNSShare Buyback
24th Mar 20267:00 amRNSFull year results
20th Mar 202611:25 amRNSShare Buyback
19th Mar 202611:20 amRNSShare Buyback
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20269:58 amRNSShare Buyback
6th Mar 20267:00 amRNSShare Buyback
5th Mar 20267:00 amRNSNotice of Results
3rd Mar 20267:00 amRNSThree-year Hematology purchasing agreement
2nd Mar 20263:30 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSShare Buyback
19th Feb 20267:00 amRNSShare Buyback Programme
2nd Feb 20267:00 amRNSShare Buyback & Completion of Buyback Programme
30th Jan 20267:00 amRNSShare Buyback
29th Jan 20267:00 amRNSShare Buyback
28th Jan 202611:41 amRNSShare Buyback
27th Jan 20267:00 amRNSFY 2025 Trading Update
15th Jan 20267:00 amRNSShare Buyback
14th Jan 202611:43 amRNSShare Buyback
14th Jan 20269:37 amRNSShare Buyback
12th Jan 20269:45 amRNSShare Buyback
9th Jan 20265:00 pmRNSShare Buyback
8th Jan 20269:40 amRNSShare Buyback
6th Jan 20266:03 pmRNSShare Buyback
2nd Jan 202610:23 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
16th Dec 20251:57 pmRNSShare Buyback
16th Dec 20257:00 amRNSExecutive Chair share purchase
8th Dec 20257:00 amRNSCancellation of Treasury Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.